Izervay

(avacincaptad pegol)

ApprovedSmall molecule

Astellas

Izervay is one of 101 small molecule programs targeting Macular Degeneration. It is currently in Approved.

Indications

Total Trials

Active Trials

100

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Macular DegenerationActive, not recruiting

Polypoidal Choroidal VasculopathyActive, not recruiting

Geographic AtrophyActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Macular DegenerationPhase 2

Active, not recruiting

Polypoidal Choroidal VasculopathyPhase 2

Active, not recruiting

Geographic AtrophyApproved

Active, not recruiting

Age-Related Macular DegenerationPhase 1

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

64 2

Eylea

Regeneron

Phase 3

44 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Izervay

Astellas

Approved

3 8

Retaane

AAlcon Research

Phase 3

5 9

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 10

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedActive, not recruiting

Geographic Atrophy

NCT06970665

Q4 2030

Recruiting

Geographic Atrophy

NCT06779773

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration3 trials

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Completed·UUnknown Sponsor·Phase 2/3·NCT02686658·286 enrolled

A Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular Degeneration

Completed·OOphthotech Corporation·Phase 1·NCT00950638·47 enrolled

ARC1905 (Anti-C5 Aptamer) Given With Lucentis 0.5 mg In People With Neovascular Age-Related Macular Degeneration

Completed·OOphthotech Corporation·Phase 1·NCT00709527·60 enrolled

Geographic Atrophy3 trials

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Completed· Astellas logo

Astellas·Phase 3·NCT05536297·278 enrolled

A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY™) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular Degeneration

Recruiting· Astellas logo

Astellas··NCT06779773·500 enrolled

A Phase 3/4, Multicenter, Single-arm Clinical Study to Assess the Safety of Intravitreal Administration of ASP3021 in Participants in Japan With Geographic Atrophy Secondary to Age-related Macular Degeneration

Active, not recruiting· Astellas logo

Astellas·Approved·NCT06970665·17 enrolled

Autosomal Recessive1 trial

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Completed· Astellas logo

Astellas·Phase 2·NCT03364153·121 enrolled

Polypoidal choroidal vasculopathy1 trial

A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Completed·OOphthotech Corporation·Phase 2·NCT02397954·4 enrolled

Safety and Efficacy1 trial

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Completed·UUnknown Sponsor·Phase 3·NCT04435366·448 enrolled

2 more indications

Neovascular AMD1 trial

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Terminated·UUnknown Sponsor·Phase 2·NCT05571267·1 enrolled

Macular Degeneration1 trial

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Completed·OOphthotech Corporation·Phase 2·NCT03362190·64 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 4, 2023

IZERVAY

NDA NDA217225

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for avacincaptad pegol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — avacincaptad pegol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for avacincaptad pegol. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA217225). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Izervay. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Astellas

Patent Landscape[5]

Patent Cliff

Nov 11, 2026

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8236773Nov 11, 2026

9617546Feb 14, 2027

7579456Feb 14, 2027

11491176Jul 11, 2034

11273171Jul 11, 2034

1 more patents

12016875Jul 11, 2034

Izervay

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2030

Trials by Indication[1]

Age-Related Macular Degeneration3 trials

Geographic Atrophy3 trials

Autosomal Recessive1 trial

Polypoidal choroidal vasculopathy1 trial

Safety and Efficacy1 trial

Neovascular AMD1 trial

Macular Degeneration1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News